Guided Therapeutics (GTHP) Non-Current Assets (2010 - 2025)
Guided Therapeutics (GTHP) reported Non-Current Assets of $719000.0 for Q4 2025, up 297.24% on a YoY basis from $181000.0 in Q4 2024, and up 591.35% sequentially from $104000.0 in Q3 2025.
Guided Therapeutics (GTHP) Non-Current Assets (2010 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 16 years of Non-Current Assets data on file, last reported at $719000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Assets rose 297.24% year-over-year to $719000.0; the trailing twelve-month figure through Dec 2025 stood at $719000.0 (up 297.24% YoY), and the FY2025 full-year result was $719000.0, up 297.24% from the prior year.
- Non-Current Assets advanced to $719000.0 in Q4 2025, from $104000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $719000.0 in Q4 2025 to a low of $104000.0 in Q3 2025.
- A 5-year average of $322450.0 and a median of $330500.0 in 2023 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets soared 570.97% in 2021 and tumbled 49.51% in 2025, its largest moves.
- Tracing GTHP's Non-Current Assets over 5 years: stood at $403000.0 in 2021, then dropped by 10.17% to $362000.0 in 2022, then fell by 23.76% to $276000.0 in 2023, then slumped by 34.42% to $181000.0 in 2024, then surged by 297.24% to $719000.0 in 2025.
- Business Quant data shows GTHP's Non-Current Assets at $719000.0 in Q4 2025, $104000.0 in Q3 2025, and $129000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 84.92 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 32.95 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 68.24 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 35.67 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 7.09 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 2.30 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 20.47 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 26.70 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 6.35 Bn |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | 719,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 719,000.00 |
| Sep 30, 2025 | 104,000.00 |
| Jun 30, 2025 | 129,000.00 |
| Mar 31, 2025 | 156,000.00 |
| Dec 31, 2024 | 181,000.00 |
| Sep 30, 2024 | 206,000.00 |
| Jun 30, 2024 | 230,000.00 |
| Mar 31, 2024 | 254,000.00 |
| Dec 31, 2023 | 276,000.00 |
| Sep 30, 2023 | 299,000.00 |
| Jun 30, 2023 | 319,000.00 |
| Mar 31, 2023 | 342,000.00 |
| Dec 31, 2022 | 362,000.00 |
| Sep 30, 2022 | 380,000.00 |
| Jun 30, 2022 | 400,000.00 |
| Mar 31, 2022 | 400,000.00 |
| Dec 31, 2021 | 403,000.00 |
| Sep 30, 2021 | 416,000.00 |
| Jun 30, 2021 | 427,000.00 |
| Mar 31, 2021 | 446,000.00 |